NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and prefere

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultatior medicines for healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines in are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
    - how well the medicine works,
    - which patients might benefit from it ,
    - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
    - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health a Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGGC?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision

birch bark extract Filsuvez® SMC2651	07/10/2024	treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
Cemiplimab Libtayo SMC 2724	07/10/2024	In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: •locally advanced NSCLC who are not candidates for definitive chemoradiation, or •metastatic NSCLC.	Not routinely available as not recommended for use in NHSScotland	07/10/2024
dabrafenib Finlee® SMC2667	07/10/2024	In combination with trametinib (Spexotras®) for: - the treatment of paediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. - the treatment of paediatric patients aged 1 year and older with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and / or chemotherapy treatment.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
dasatinib NCMAG116	07/10/2024	Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) integrated with chemotherapy	Routinely available in line with local or regional guidance	07/10/2024

Medicine		Condition being treated	NHSGGC Decision	Date of decision
dasatinib NCMAG117	07/10/2024	Dasatinib for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy	Routinely available in line with local or regional guidance	07/10/2024
Drosperinone Slynd SMC 2725	07/10/2024	Contraception	Not routinely available as not recommended for use in NHSScotland	07/10/2024
elranatamab Elrexfio® SMC2669	07/10/2024	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
epcoritamab Tepkinly® SMC2632	07/10/2024	Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Routinely available in line with local or regional guidance	07/10/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
etranacogene dezaparvovec 07/10/2024 Hemgenix® SMC2649	treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
faricimab 07/10/2024 Vabysmo SMC 2685	Treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
follitropin delta 07/10/2024 Rekovelle® SMC2670	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative	07/10/2024
glofitamab 07/10/2024 Columvi® SMC2614	Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.	Routinely available in line with local or regional guidance	07/10/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
ivacaftor, lumacaftor 07/10/2024 Orkambi® SMC2712	treatment of cystic fibrosis (CF) in patients aged 1 year and older (granules in sachet) or 6 years and older (film-coated tablets) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	Routinely available in line with national guidance	07/10/2024
ivacaftor, tezacaftor 07/10/2024 Symkevi® SMC2711	In a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.	Routinely available in line with national guidance	07/10/2024
ivacaftor, tezacaftor, elexacaftor 07/10/2024 Kaftrio® SMC2713	In a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 2 years to less than 6 years (granules in sachet) and 6 years and older (film-coated tablets) who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Routinely available in line with national guidance	07/10/2024
ivosidenib 07/10/2024 Tibsovo® SMC2664	Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024

Medicine		Condition being treated	NHSGGC Decision	Date of decision
mavacamten Camzyos® SMC2618	07/10/2024	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
momelotinib Omjjara® SMC2636	07/10/2024	Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Routinely available in line with local or regional guidance	07/10/2024
nivolumab Opdivo SMC 2726	07/10/2024	In combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.	Not routinely available as not recommended for use in NHSScotland	07/10/2024
nivolumab, relatlimab Opdualag® SMC2645	07/10/2024	First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024

Medicine		Condition being treated	NHSGGC Decision	Date of decision
pegcetacoplan Aspaveli® SMC2715	07/10/2024	Monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.	Not routinely available as not recommended for use in NHSScotland	07/10/2024
pegunigalsidase alfa Elfabrio® SMC2665	07/10/2024	for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
pembrolizumab Keytruda SMC 2689	07/10/2024	As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
pembrolizumab Keytruda® SMC2660	07/10/2024	in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024

Medicine		Condition being treated	NHSGGC Decision	Date of decision
Relugolix Orgovyx SMC 2678	07/10/2024	•For the treatment of adult patients with advanced hormone-sensitive prostate cancer •for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy •as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
Rezafungin Rezzayo SMC 2659	07/10/2024	Treatment of invasive candidiasis in adults	Routinely available in line with local or regional guidance	07/10/2024
Selinexor Nexpovio SMC 2674	07/10/2024	In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
Selinexor Nexpovio SMC 2673	07/10/2024	In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024

Medicine		Condition being treated	NHSGGC Decision	Date of decision
Semaglutide Wegovy SMC2497	07/10/2024	An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of •≥30kg/m2 (obesity), or •≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
teclistamab Tecvayli® SMC2668	07/10/2024	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
tirzepatide Mounjaro® SMC2653	07/10/2024	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024
trifluridine, tipiracil Lonsurf® SMC2654	07/10/2024	In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	07/10/2024

Medicine		Condition being treated	NHSGGC Decision	Date of decision
volanesorsen Waylivra® SMC2716	07/10/2024	As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.	Not routinely available as not recommended for use in NHSScotland	07/10/2024
zilucoplan Zilbrysq® SMC 2717	07/10/2024	As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as not recommended for use in NHSScotland	07/10/2024